MedTrace Logo

Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment

NCT03053219 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-02-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced NSCLC who participant in \[14C\] AC0010 ADME.

Conditions

  • Carcinoma，Non-Small-Cell Lung

Interventions

DRUG

AC0010

Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours

Sponsors & Collaborators

  • Hangzhou ACEA Pharmaceutical Research Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lingxiang Liu, Doctor · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-07-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03053219 on ClinicalTrials.gov